47 results on '"Mittereder, Lara"'
Search Results
2. Pharmacological Inhibition of Host Heme Oxygenase-1 Suppresses Mycobacterium tuberculosis Infection In Vivo by a Mechanism Dependent on T Lymphocytes
3. Heme oxygenase-1 inhibition promotes IFNγ- and NOS2-mediated control of Mycobacterium tuberculosis infection
4. Intravenous BCG Vaccination of Diversity Outbred Mice Results in Moderately Enhanced Protection against Challenge with Mycobacterium tuberculosis Compared to Intradermal Vaccination
5. The Dysbiosis Triggered by First-Line Tuberculosis Antibiotics Fails to Reduce Their Bioavailability
6. IL-12p40 is essential but not sufficient for Francisella tularensis LVS clearance in chronically infected mice
7. Mycobacterium tuberculosis Induces Irg1 in Murine Macrophages by a Pathway Involving Both TLR-2 and STING/IFNAR Signaling and Requiring Bacterial Phagocytosis
8. Enhancement of CD4+ T Cell Function as a Strategy for Improving Antibiotic Therapy Efficacy in Tuberculosis: Does It Work?
9. IFNs Reset the Differential Capacity of Human Monocyte Subsets to Produce IL-12 in Response to Microbial Stimulation
10. Production of IFN-γ by splenic dendritic cells during innate immune responses against Francisella tularensis LVS depends on MyD88, but not TLR2, TLR4, or TLR9
11. Correlation between Disease Severity and the Intestinal Microbiome in Mycobacterium tuberculosis-Infected Rhesus Macaques
12. A major role for ferroptosis in Mycobacterium tuberculosis–induced cell death and tissue necrosis
13. Enhancement of CD4+ T Cell Function as a Strategy for Improving Antibiotic Therapy Efficacy in Tuberculosis: Does It Work?
14. A panel of correlates predicts vaccine-induced protection of rats against respiratory challenge with virulent Francisella tularensis
15. Additional file 5: Figure S5. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
16. Additional file 2: Figure S2. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
17. Additional file 8: Figure S8. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
18. Additional file 4: Figure S4. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
19. A panel of correlates predicts vaccine-induced protection of rats against respiratory challenge with virulent Francisella tularensis
20. Inhibition of mTORC1 activity is required for the IL-12p40 response of classical CD16neg CD14+ primary human monocytes to Toxoplasma gondii
21. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
22. Inhibition of heme oxygenase-1 activity suppresses Mycobacterium tuberculosis infection in vivo by a mechanism dependent on T lymphocytes and IFN-γ production
23. Water-in-Oil–Only Adjuvants Selectively Promote T Follicular Helper Cell Polarization through a Type I IFN and IL-6–Dependent Pathway
24. Enhancing CD4+ T cell function as a strategy for improving antibiotic therapy of Mycobacterium tuberculosis infection
25. Activities of Murine Peripheral Blood Lymphocytes Provide Immune Correlates That Predict Francisella tularensis Vaccine Efficacy
26. The IL-12 Response of Primary Human Dendritic Cells and Monocytes to Toxoplasma gondii Is Stimulated by Phagocytosis of Live Parasites Rather Than Host Cell Invasion
27. Francisella tularensis Vaccines Elicit Concurrent Protective T- and B-Cell Immune Responses in BALB/cByJ Mice
28. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer
29. Abstract A198: Identification and preclinical testing of novel targeted therapies for human triple-negative breast cancer.
30. Activities of Murine Peripheral Blood Lymphocytes Provide Immune Correlates That Predict Francisella tularensisVaccine Efficacy
31. Additional file 7: Figure S7. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
32. Additional file 12: Figure S12. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
33. Additional file 10: Figure S10. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
34. Additional file 6: Figure S6. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
35. Additional file 1: Figure S1. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
36. Additional file 9: Figure S9. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
37. Additional file 12: Figure S12. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
38. Additional file 6: Figure S6. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
39. Additional file 11: Figure S11. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
40. Additional file 11: Figure S11. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
41. Additional file 9: Figure S9. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
42. Additional file 3: Figure S3. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
43. Additional file 10: Figure S10. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
44. Additional file 7: Figure S7. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
45. Additional file 1: Figure S1. of Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
46. Pharmacological Inhibition of Host Heme Oxygenase-1 Suppresses Mycobacterium tuberculosisInfection In Vivoby a Mechanism Dependent on T Lymphocytes
47. Enhancement of CD4 + T Cell Function as a Strategy for Improving Antibiotic Therapy Efficacy in Tuberculosis: Does It Work?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.